71 Participants Needed

Peer Support Program for Quitting Vaping

(V2V Trial)

DS
Overseen ByDante Simone
Age: < 65
Sex: Any
Trial Phase: Academic
Sponsor: University of Massachusetts, Worcester
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The dramatic increase in the use of e-cigarettes among U.S. adolescents has been called a national epidemic, with more adolescents now using e-cigarettes than traditional cigarettes. The high amounts of nicotine in e-cigarettes harm adolescents and put them at greater risk of becoming traditional cigarette smokers. The investigators propose to develop Vaper-to-Vaper (V2V), a suite of mobile peer driven tools including peer texting and coaching based on lessons learned in the investigators' prior tobacco intervention work, to engage and help adolescents use strategies to manage cravings and successfully quit.

Research Team

Rajani Sadasivam, PhD

Rajani Sadasivam, PhD

Principal Investigator

University of Massachusetts Chan Medical School

LP

Lori Pbert, PhD

Principal Investigator

University of Massachusetts Chan Medical School

Eligibility Criteria

This trial is for high school students in grades 9-12 who currently use e-cigarettes and can communicate in English or Spanish. Participants must have used an e-cigarette at least once in the past week and own a smartphone. Those unable to give informed consent or assent are excluded.

Inclusion Criteria

Have a smartphone
I am a high school student in grades 9-12.
Current e-cigarette user, as defined as a response greater than '0 days' to the question: 'During the past 7 days, on how many days did you use e-cigarettes?' This eligibility criterion is modeled on a question in the 2018 National Youth Tobacco Survey (NYTS), a survey of U.S. middle and high school students which used a 30-day timeframe.

Exclusion Criteria

I am unable or unwilling to give informed consent.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention Development

A peer advisory panel of 20 adolescent e-cigarette users participates in a qualitative assessment and further development of V2V components

Not specified

Pilot Feasibility Study

Eighty adolescent e-cigarette users from 4 high schools are recruited and followed for 6 months to evaluate the feasibility and acceptability of the V2V intervention

6 months

Follow-up

Participants are monitored for safety and effectiveness after the intervention, including measures of abstinence, self-efficacy, and nicotine addiction

3 months

Treatment Details

Interventions

  • E-Cigarette Cessation Materials
  • Gamification
  • Peer Coaching via Text
  • Peer Messaging
Trial Overview The study tests Vaper-to-Vaper (V2V), a mobile tool suite that includes peer texting, coaching, gamification, and cessation materials designed to help adolescents quit vaping by managing cravings.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment3 Interventions
Students in schools randomized to the intervention will receive: (1) peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit; (2) peer coaching, facilitated by texting; and (3) gamification, designed to motivate participation.
Group II: ControlActive Control1 Intervention
Students in schools randomized to the control condition will be provided e-cigarette cessation materials by the Research Coordinator at the time of study enrollment.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Massachusetts, Worcester

Lead Sponsor

Trials
372
Recruited
998,000+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials
2,658
Recruited
3,409,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security